GB2290539A - Indole and benzimidazole gastrin and CCK antagonists - Google Patents

Indole and benzimidazole gastrin and CCK antagonists Download PDF

Info

Publication number
GB2290539A
GB2290539A GB9502503A GB9502503A GB2290539A GB 2290539 A GB2290539 A GB 2290539A GB 9502503 A GB9502503 A GB 9502503A GB 9502503 A GB9502503 A GB 9502503A GB 2290539 A GB2290539 A GB 2290539A
Authority
GB
United Kingdom
Prior art keywords
compound
benzimidazole
formula
acid
boc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9502503A
Other versions
GB9502503D0 (en
Inventor
Atul Kotecha
Robert Antony David Hull
Nigel Paul Shankley
Elaine Anne Harper
Sarkis Barret Kalindjian
Sonia Patricia Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
James Black Foundation Ltd
Original Assignee
James Black Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410688A external-priority patent/GB9410688D0/en
Priority claimed from PCT/GB1994/001741 external-priority patent/WO1995004720A2/en
Application filed by James Black Foundation Ltd filed Critical James Black Foundation Ltd
Publication of GB9502503D0 publication Critical patent/GB9502503D0/en
Priority to PCT/GB1995/001194 priority Critical patent/WO1995032949A1/en
Priority to AT95919561T priority patent/ATE235470T1/en
Priority to US08/737,725 priority patent/US5912260A/en
Priority to DE69530081T priority patent/DE69530081T2/en
Priority to AU25342/95A priority patent/AU2534295A/en
Priority to JP8500483A priority patent/JPH10504525A/en
Priority to EP95919561A priority patent/EP0763026B1/en
Publication of GB2290539A publication Critical patent/GB2290539A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of the formula <IMAGE> wherein L is=N- or =CH-, one of X and Y is -NH-CH2-R<2> (wherein R<2> is cycloheptyl or 1-adamantyl) and the other is <IMAGE> in which R<1> is H or methyl, T<1> and T<2> are independantly H or Z(CH2)m-, wherein m is from 0 to 3 and Z carboxy group, a tetrazolyl group, CF3CONHSO2-, PhCONHSO2- or a group selected from <IMAGE> (provided that T<1> and T<2> are not both H and that T<1> and T<2> are not both carboxy when L is =CH-); and n is from 0 to 5 and pharmaceutically acceptable salts and precursors thereof are potent gastrin and/or CCK antagonists.

Description

Gastrin and CCK antagonists This invention relates to gastrin and CCK antagonists. The invention also relates to methods for preparing such antagonists and to pharmaceutical compositions comprising such antagonists.
Gastrin and the-CCK's are structurally-related neuropeptides which exist in gastrointestinal tissue and in the CNS (see Mutt V., Gastrointestinal Hormones, Glass G.B.J., ed., Raven Press, N.Y., p 169 and Nisson G., ibid, p. 127).
Gastrin is one of the three primary stimulants of gastric acid secretion. Several forms of gastrin are found including 34-, 17-, and 14-amino acid species with the minimum active fragment being the C-terminal tetrapeptide (TrpMetAspPhe-NH2) which is reported in the literature to have full pharmacological activity (see Tracey H.J. and Gregory R.A., Nature (London), 1964, 204, 935). Much effort has been devoted to the synthesis of analogues of this tetrapeptide (and the N-protected derivative Boc TrpMetAspPhe-NH2) in an attempt to elucidate the relationship between structure and activity.
Natural cholecystokinin is a 33 amino acid peptide (CCK-33), the C-terminal 5 amino acids of which are identical to those of gastrin. Also found naturally is the C-terminal octapeptide (CCK-8) of CCK-33.
The cholecystokinins are reported to be important in the regulation of appetite. They stimulate intestinal motility, gall bladder contractin, pancreatic enzyme secretion, and are known to have a trophic action on the pancreas. They also inhibit gastric emptying and have various effects in the CNS.
Compounds which bind to gastrin and/or CCK receptors are important because of their potential pharmaceutical use as antagonists of the natural peptides.
A number of gastrin antagonists have been proposed for various therapeutic applications, including the prevention of gastrin-related disorders, gastrointestinal ulcers, Zollinger-Ellison syndrome, antral G cell hyperplasia and other conditions in which lowered gastrin activity is desirable. The hormone has also been shown to have a trophic action on cells and so an antagonist may be expected to be useful in the treatment of cancers, particularly in the stomach and the colon.
Possible therapeutic uses for cholecystokinin antagonists include the control of appetite disorders such as anorexia nervosa, and the treatment of pancreatic inflammation, biliary tract disease and various psychiatric disorders.
Other possible uses are in the potentiation of opiate (e.g.
morphine) analgesia, and in the treatment of cancers, especially of the pancreas. Moreover, ligands for cholecystokinin receptors in the brain (so-called CCK8 receptors) have been claimed to possess anxiolytic activity.
The present invention provides compounds of the formula
wherein L is =N- or =CH-, one of X and Y is -NH-CH2-R2 (wherein R2 is cycloheptyl or l-adamantyl) and the other is
in which Rl is H or methyl, Tl and T2 are independently H or Z(CH2)m-, wherein m is from 0 to 3 and Z is a carboxy group, a tetrazolyl group, CF3CONHSO2-, PhCONHSO2- or a group selected from
(provided that Tl and T2 are not both H and that T and T2 are not both carboxy when L is =CH-); and n is from 0 to 5 Such compounds have been found to act as gastrin and/or CCK antagonists in in vitro tests. Most importantly, they have been found to be active when administered orally.
The compounds of the invention exist in enantiomeric and tautomeric forms. It will be understood that the invention comprehends the different enantiomers and tautomers in isolation from each other, and also as mixtures.
The invention also comprehends derivative compounds ("prodrugs") which are degraded in vivo to yield the species of formula (I). Pro-drugs are usually (but not always) of lower potency at the target receptor than the species to which they are degraded. Pro-drugs are particularly useful when the desired species has chemical or physical properties which make its administration difficult or inefficient. For example, the desired species may be only poorly soluble, it may be poorly transported across the mucosal epithelium, or it may have an undesirably short plasma half-life. Further discussion of pro-drugs may be found in Stella, V. J. et al, "Prodrugs", Drug Deliverv Svstems, pp. 112-176 (1985), and Drugs, 29, pp.455-473 (1985).
The compounds of the invention may be prepared by reacting a compound of the formula
with a compound of the formula H2N-CH2-R2 wherein L and R2 are as defined above, and then reacting the product with a compound of the formula
wherein Rl and n are as defined above, and T3 and T4 are independently H or Z'(CH2)=- (wherein m is from 0 to 3 and Z' is a protected carboxy group, a protected tetrazolyl group, CF3CONHSO2- or PhCONHSO2-). Alternatively, the compound of formula (III) is first reacted with the compound of formula (IV) and the product is then reacted with the compound of formula H2N-CH2-R2. In the case in which Z' is a protected group, the protecting group is then removed.
Suitable amidation methods are described in detail in "The Peptides, Vol. 1", Gross and Meinenhofer, Eds., Academic Press, N.Y., 1979. These include the carbodiimide method (using, for example, 1,3-dicyclohexylcarbodiimide [DCC] or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimidehydrochloride [EDCI], and optionally an additive such as l-hydroxybenzotriazole [HOBT] to prevent racemization), the azide method, the mixed anhydride method, the symmetrical anhydride method, the acid chloride method, the acid bromide method, the use of bis (2-oxo-3-oxazolidinyl) phosphinic chloride [BOP-Cl), the use of PyBOP or PyBrOP, the use of the isopropenylsuccinimido carbonate method and the active ester method (using, for example, N-hydroxysuccinimide esters, 4nitrophenyl esters or 2,4,5-trichlorophenol esters).
The coupling reactions are generally conducted under an inert atmosphere, such as an atmosphere of nitrogen or argon. Suitable solvents for the reactants include methylene chloride, tetrahydrofuran [THF], dimethoxyethane [DME] and dimethylformamide [DMF].
The compounds of the invention in which Z is a group of the formula
may be prepared from suitable precursors such as the corresponding aniline or alcohol, which are then functionalised using standard methods.
Pharmaceutically acceptable salts of the acidic or basic compounds of the invention can of course be made by conventional procedures, such as by reacting the free base or acid with at least a stoichiometric amount of the desired salt-forming acid or base.
While the compounds of the invention can be administered orally, the present invention also comprehends administration by other routes including parenteral, intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical administration.
For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.
Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
Effective doses of the compounds of the present invention may be ascertained by conventional methods. The specific dosage level required for any particular patient will depend on a number of factors, including the route of administration, the severity of the condition being treated and the weight of the patient. In general, however, the daily dose (whether administered as a single dose or as divided doses) will be in the range 0.01 to 5000 mg per day, and more usually from 1 to 1000 mg per day. Expressed as dosage per unit body weight, a typical dose will be between 0.1 pg/kg and 50mg/kg, and more usually between 1 Ag/kg and 50mg/kg. For oral administration a typical dose will be between 0.1 mg/kg and 20 mg/kg.
The invention is now further illustrated by means of the following examples.
Example 1 5-(lS-(3 , 5-dicarboxyphenylaminocarbonyl) -2-(2- fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)-benzimidazole a. Benzimidazole-5,6-dicarboxylic acid anhydride.
Benzimidazole-5,6-dicarboxylic acid (8.2g), prepared from 5,6-dimethylbenzimidazole as described in J.Org.Chem. 1987, 52, 2934., was heated at 250'C under vacuum (O.Olmm Hg) for lh. The solid was extracted with hot acetone and the acetone extracts were evaporated to give the title compound (6.lg).
b.5-(lS-(3,5-dibenzyloxyzarbonylphenylaminocarbonyl)-2-(2- fluorophenyl) ethylaminocarbonyl) benzimidazole-6-carboxylic acid A solution containing the anhydride produced in step a (3.22g, 17. lmmol) and lS-(3, 5-dibenzyloxycarbonyl- phenylaminocarbonyl) -2- (2-fluorophenyl) ethylamine (9. 00g, 17.lmmol), prepared as described below, in acetonitrile (170ml) was heated under reflux for lh. The mixture was cooled and allowed to stand at 5 C for 2h. The resultant white crystals were filtered and dried to afford the title compound (10.87g).
c.5-(lS-(3,5-dibenzyloxyzarbonylphenylaminocarbonyl)-2-(2- fluorophenyl) -ethylaminocarbonyl) -6- (cycloheptanemethyl- aminocarbonyl)benzimidazole.
A solution of the acid produced in step b (5.5g, 7.89mmol) and cycloheptanemethylamine (1.5g, 11.86mmol) in dry dimethylformamide (50ml) was cooled to 0 C, l-hydroxybenzotriazole (1.07g, 7.89mmol) was added and the solution was stirred for lOmin. at this temperature.
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI] (1.51g, 7.89mmol) was added followed by 4dimethylaminopyridine (catalytic quantity) and the stirring was continued for lh at 0 C then overnight at room temperature. The solvent was evaporated under reduced pressure to approximately half the original volume and the residue was poured into water (500ml). The resultant precipitate was filtered and dried and then purified by column chromatography (silica 5% methanol and 95% dichloromethane) yielding the title compound (4.95g, 76%).
d. 5-(lS-(3,5-dicarboxyphenylaminocarbonyl)-2-(2- fluorophenyl) ethylaminocarbonyl) -6- (cycloheptane- methylaminocarbonyl)benzimidazole The product of step c (4.7g, 5.7mmol) was dissolved in a THF/methanol mixture (1:1 200ml) and 10% palladium oncharcoal (500mg) was added.The reaction mixture was stirred overnight under an atmosphere of hydrogen and then filtered through celite and evaporated to yield the title compound (3.5g, 96%). 1H NMR (d6-DMSO) s 13.0 (3H, br s), 10.2 (1H, br s), 8.9 (1H, d), 8.74 (2H, s), 8.7 (1H, t), 8.4 (1H, s), 8.2 (1H, s), 7.8 (1H, s), 7.5-7.1 (5H, m), 4.8 (1H, m), 3.5 (1H, m), 3.3-3.1 (3H, m), 1.6-1.1 (13H, m).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 55.39; H, 6.85; N, 9.17. C4SH6sFN7ol7 requires C, 55.75; H, 6.63; N, 9.48% Preparation of lS-(3,5-dibenzyloxycarbonylphenyl- aminocarbonyl)-2-phenylethylamine e. 3,5-dibenzyloxycarbonylnitrobenzene 5-nitro-isophthalic acid (21.lug, 0.1 mol), thionyl chloride (80 ml) and DMF (10 drops) were stirred and heated for about lh until a clear solution was obtained. Excess thionyl chloride was removed by evaporation and the residual acid chloride was coevaporated with dichloromethane (2 x 100 ml) to remove the last traces.
Benzyl alcohol (21.6 g, 0.2 mol) and triethylamine (30.03 g, 0.3 mol) were dissolved in dichloromethane (200 ml) and stirred at 0 C under an atmosphere of dry nitrogen and a solution of the acid chloride in dichloromethane (50 ml) was added dropwise over 20 min. The solution was stirred and ref fluxed for lh, and the solution was cooled. The organic layer was washed with water (2 x 100ml), saturated sodium hydrogencarbonate solution (100 ml), and dried over magnesium sulphate. The solution was filtered and evaporated to leave the title compound (39.1g, 100%), tH NMR (CDCl3) 6 9.0 (3H, d), 7.5 (10H, m), 5.5 (4H, s).
f . 3,5-dibenzyloxycarbonylaniline 3,5-dibenzyloxycarbonylnitrobenzene (3.91g, 10 mol) was dissolved in ethyl acetate (50 ml) and tin(II)chloride dihydrate (11.27g, 50 mmol) was added and the mixture stirred and heated at 70 under an atmosphere of nitrogen for lh. The mixture was poured carefully onto 5% sodium hydrogencarbonate solution (200 ml) and a further aliquot of ethyl acetate (100 ml) was added. After shaking, the organic layer was separated and the aqueous layer was extracted with more ethyl acetate (50 ml). The combined organic layers were washed with brine, dried, filtered and evaporated to leave a pale yellow solid (3.25g, 90t), 1H NMR (CDCl3) 6 8.1 (1H, d), 7.5 (12H, m), 5.4 (4H, s), 3.8 (2H, br s).
g. N-tert-butyloxycarbonyl-1S- (3, 5-dibenzyloxycarbonyl- phenylaminocarbonyl)-2-(2-fluorophenyl)ethylamine BOC-L-2-fluorophenylalanine (2.61g, 9.2 mmol) was dissolved in dry dichloromethane (30 ml) and dry diisopropylethylamine (3.2 ml, 18.4 mmol) was added followed by PyBROP (4.3g, 9.2 mmol). The mixture was stirred at room temperature for 5 min and then 3,5-dibenzyloxycarbonylaniline (2.17 g, 6.0 mmol) was added. The solution was stirred at room temperature overnight and the solution was then washed sequentially with 5% aqueous potassium hydrogensulphate, water, saturated sodium hydrogencarbonate solution and water and finally dried, filtered and evaporated.The crude product was crystallised from ethanol to give the title compound (2.94g,.78%). H NMR (d6-DMSO) 6 10.4 (1H, s), 8.5 (2H, s), 8.2 (1H, s), 7.3 (15H, m), 5.4 (4H, s), 4.3 (1H, m), 2.9 (2H, m), 1.3 (9H,s).
h. lS-(3,5-dibenzyloxyzarbonylphenylaminocarbonyl)-2-(2- fluorophenyl)ethylamine N-tert-butyloxycarbonyl-1S- (3 , 5-dibenzyloxycarbonylphenyl- aminocarbonyl) -2- (2-fluorophenyl) ethylamine (8.0 g, 12.7 mmol) was dissolved in trifluoroacetic acid (40 ml) and stirred at room temperature for 30 min. The solvent was removed by evaporation and the residue taken up in dry dichloromethane (50 ml) and washed with saturated sodium hydrogencarbonate solution (3 x 30ml), water (30ml) and brine (30ml). The solution was dried over anhydrous sodium sulphate, filtered and evaporated to give the title compound (6.5g,98%). 1H NMR (d6-DMSO) 6 8.5 (2H,s), 8.2 (lH,s), 7.3 (14H,m), 5.4 (4H,s), 3.6 (lH,m), 2.9 (lH,m), 2.8 (1H,m).
Example 2 (i) -5- (1(3, 5-dicarboxyphenylaminocarbonyl) -2- (2,3, 4-trifluorophenyl) ethylaminocarbonyl) -6- (1 cycloheptanemethylaminocarbonyl) benz imidazole The material was prepared essentially as in example 1 except that (+)-BOC-2,3,4-trifluorophenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine. 1H NMR (d6-DMSO) 6 10.2 (1H, s),8.90 (1H, d), 8.70 (3H, m), 8.4 (1H, s), 8.2 (1H, s), 7.9 (1H, s), 7.3 (2H, m), 7.2 (2H, s), 4.9 (1H, m), 3.6 (1H, dd), 3.1 (3H, m), 1.6-1.1 (13H, m).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 55.49; H, 6.33; N, 9.21. C48HF3N7Q7 requires C, 53.88 H, 6.22; N, 9.16%.
Example 3 5-(lS-(3 , 5-dicarboxyphenylaminocarbonyl) -2-(3- fluorophenyl) ethylaminocarbonyl) -6- (1-cycloheptanemethyl- aminocarbonyl)benzimidazole The material was prepared essentially as in example 1 except that BOC-L-3-fluorophenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine. 'H NMR (d6-DMSO) 6 10.2 (1H, s), 8.9 (1H, s), 8.7 (2H, d), 8.7 (1H, t), 8.4 (1H, s),8.2 (1H, t), 7.8 (1H, br s), 7.4 (1H, m), 7.2 (2H, m), 7.1 (2H, m), 4.8 (1H, m), 3.5 (1H, dd), 3.1 (2H, m), 3.0 (1H, dd), 1.7-1.1 (13H, m).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 53.16; H, 6.91; N, 9.18. C48H68F3N7017 .2.7H2O requires C, 53.27; H, 6.83; N, 9.06%.
Example 4 5-(1S-(3 ,5-dicarboxyphenylaminocarbonyl) -2-(2 fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 1 except that 1adamantanemethylamine was used in step c instead of cycloheptanemethylamine. 'H NMR (d6-DMSO) 6 13.0 (3H, br s), 10.2 (1H, s), 8.9 (1H, d), 8.7 (2H, s), 8.6 (1H, t), 8.4 (1H, s), 8.2 (1H, s), 7.9 (1H, d), 7.4-7.2 (4H, m), 7.1 (1H, s), 4.8 (1H, m), 3.6-2.9 (4H, m), 1.8 (3H, s), 1.6 (6H, m), 1.3 (6H, m).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt found: C, 55.19; H, 6.77; N, 8.66.
CSlH70FN7Ol7 requires C, 55.10; H, 6.75; N, 8.82% Example 5 5-(1S-(3, 5-dicarboxyphenylaminocarbonyl) -2-(3- fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 4 except that that BOC-L-3-fluorophenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine. 1H NMR (d6-DMSO) 8 13.0 (3H, br s), 10.2 (1H, s), 8.9 (1H, d), 8.7 (2H, s), 8.5 (1H, t), 8.4 (1H, s), 8.2 (1H, s), 7.9 (1H, s), 7.4 (1H, m), 7.2 (4H, m), 4.8 (1H, m), 3.6-2.9 (4H, m), 1.8 (3H, s), 1.7 (6H, q), 1.5 (6H, s).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 55.11; H, 6.84; N, 8.90. CslH70FN7ol7 .2H2O requires C, 55.27; H, 6.73; N, 8.85% Example 6 5(15- (3, 5-dicarboxyphenylaminocarbonyl) -2- (4- fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 4 except that BOC-L-4-fluorophenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine. 1H NMR (d6-DMSO) 8 13.0 (3H, br s), 10.2 (1H, s), 8.9 (1H, d), 8.7 (2H, s), 8.5 (1H, t), 8.4 (1H, s), 8.2 (1H, s), 7.9 (1H, s), 7.4 (2H, m), 7.2 (3H, m), 4.8 (1H, m), 3.6-2.9 (4H, m), 1.8 (3H, s), 1.7 (6H, q), 1.5 (6H, s).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt Found: C, 55.32; H, 6.61; N, 8.74. C51H70FN7O17 . 2H2O requires C, 55.27; H, 6.73; N, 8.85% Example 7 (#)-5-(1-(3,5-dicarboxyphenylaminocarbonyl)-2- pentafluorophenylethylaminocarbonyl) -6- (1-adamantanemethyl aminocarbonyl ) benz imidazole This was prepared essentially as in example 4 except that (#)-BOC-pentafluorophenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine. tH NMR (d6-DMSO) 6 13.0 (2H, br s), 10.2 (1H, s), 8.9 (1H, d), 8.6 (2H, d), 8.5 (1H, t), 8.4 (1H, s), 8.2 (1H, d), 7.9 (1H, s), 7.4 (1H, s), 4.8 (1H, m), 3.5 (1H, dd), 3.2 (1H, dd), 3.0 (2H, d), 1.9 (3H, s), 1.5 (6H, q), 1.4 (6H, s).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 50.83; H, 6.04; N, 8.17. C,,H,F,N,O,, # 3 # 3H2O requires C, 50.87; H, 6.08;; N, 8.14% Example 8 (#) - 5-(1-(3,5-dicarboxyphenylaminocarbonyl)-2- (2,4-difluorophenyl)ethylaminocarbonyl)-6-(1adamantanemethylaminocarbonyl)benzimidazole This was prepared essentially as in example 4 except that that (+)-BOC-2,4-difluorophenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine. 'H NMR (d6-DMSO) 6 13.2 (3H, br s), 10.2 (lH, s), 8.9 (1H, d), 8.7 (2H, d), 8.6 (1H, t), 8.4 (1H, s), 8.2 (1H, t), 7.5 (1H, m), 7.3 (2H, m), 7.2 (1H, s), 7.1 (1H, m), 4.8 (1H, m), 3.5 (1H, dd), 3.0 (3H, m), 1.9 (3H, s), 1.6 (6H, q), 1.5 (6H, s).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 52.83; H, 6.76; N, 8.26. C51H69F2N7O17 . 4H2O requires C, 52. 67 H, 6.68; N, 8.43% Example 9 5-(lS-(3,5-dicarboxyphenylaminocarbonyl)-2- phenylethyl- (N-methylamino) -carbonyl) -6- (1-adamantane- methylaminocarbonyl)benzimidazole This was prepared essentially as in example 4 except that that BOC-N-methyl-L-phenylalanine was used in step g instead of BOC-L-2-fluorophenylalanine, 1H NMR (d6-DMSO) was consistent with the desired structure as a mixture of tautomers.
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 55.69; H, 7.04; N, 8.65. C52H73N7OI7 .2H2O requires C, 56.56; H, 7.03; N, 8.88% Example 10 5(15- (3, 5-ditetrazolylphenylaminocarbonyl) -2- phenylethylaminocarbonyl) -6- (1-adamantanemethylamino- carbonyl)benzimidazole a. Bis pivaloyloxymethyl derivative of 1S-(3,5-ditetrazolyl- phenylaminocarbonyl)-2-phenylethylamine.
5-nitro-isophthalic acid was converted to 5-nitro-3cyanobenzonitrile via the bis primary amide. Treatment with sodium azide in hot DMF gave the bis tetrazole which was derivatised with POM chloride. Catalytic hydrogenation of the nitro group gave the aniline, which was coupled with BOC-L-phenylalanine using PyBROP then treated with trifluoroacetic acid to leave the title compound.
b. Bis pivaloyloxymethyl derivative of 5-(1S-(3,5- ditetrazolylphenylaminocarbonyl) -2-phenylethylamino- carbonyl) -6- (1-adamantanemethylaminocarbonyl) benzimidazole This was prepared essentially as in example 1 steps b and c but using the product of this example step a as substrate in step b instead of lS-(3,5-dibenzyloxycarbonylphenyl- aminocarbonyl) -2- (2-fluorophenyl) ethylamine and using 1 adamantanemethylamine in place of cycloheptanemethylamine in step c.
c. 5-(1S-(3,5-ditetrazolylphenylaminocarbonyl)-2- phenylethylaminocarbonyl) -6- (1-adamantanemethylamino- carbonyl)benzimidazole The bis POM derivative prepared in step b (890 mg) was dissolved in saturated methanolic ammonia solution (20 ml) and stirred at room temperature for 5h. The volatile material was removed by evaporation to leave the title compound (740 mg) as its bis ammonium salt, Found: C, 57.36; H, 6.06; N, 27.17. C37H43N1503 .1.5 H2O requires C, 57.50; H, 5.99; N, 27.18% , 1H NMR (d6-DMSO) 6 10.2 (1H, s), 8.8 (1H, d), 8.6 (2H, d), 8.4 (2H, m), 7.9 (1H, s), 7.4 -7.2 (7H, m), 4.8 (1H, m), 3.5-3.0 (4H, m), 1.8 (3H, s), 1.5 (6H, q), 1.4 (6H, s).
Example 11 5-(lS-(3,5-ditetrazolylphenylaminocarbonyl)-2- (2-fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 10 except that BOC-L-2-fluorophenylalanine was used in step a instead of BOC-L-phenylalanine. The compound was isolated and tested as its bis ammonium salt. Found: C, 54.97; H, 5.92; N, 26.06.
C37H42FN1503 .2.5 H2O requires C, 54.94; H, 5.85; N, 25.97% . 'H NMR (d6-DMSO) 6 10.1 (1H, s), 8.8 (1H, d), 8.4 (5H, m), 7.9 (1H, s), 7.5 (1H, t), 7.4 (1H, t), 7.3 (3H, m), 4.8 (1H, m), 3.6-2.9 (4H, m), 1.8 (3H, s), 1.5 (6H, q), 1.4 (6H, s).
Example 12 5(15- (3, 5-ditetrazolylphenylaminocarbonyl) -2- (3-fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 10 except that BOC-L-3-fluorophenylalanine was used in step a instead of BOC-L-phenylalanine. The free ditetrazole was obtained on treating the bis ammonium salt with hydrochloric acid. 1H NMR (d6-DMSO) 6 10.4 (1H, s), 9.5 (1H,s), 9.2 (1H, md, 8.8(3H,m),8.5 (1H, s), 8.0 (1H, s), 7.5 (1H, dd), 7.4 (2H, m), 7.2 (2H, m), 7.1(1H,m),4.9 (1H, m), 3.5 (1H, dd), 3.1 (1H,t),2.9(3H,m),1.8 (3H, s), 1.5 (6H, q), 1.4 (6H, s).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 50.34; H, 6.40; N, 17.59. C51H70FN15O13 .5.0H20 requires C, 50.61; H, 6.66; N, 17.36% Example 13 5-(lS-(3,5-ditetrazolylphenylaminocarbonyl)-2- phenylethylaminocarbonyl) -6- (cycloheptanemethylamino- carbonyl)benzimidazole .
This was prepared essentially as in example 10 except that cycloheptanemethylamine was used in step c in place of 1adamantanemethylamine. The free ditetrazole was obtained on treating the bis ammonium salt with hydrochloric- acid. 1H NMR (d6-DMSO) 6 10.4 (1H, s), 8.9 (1H, d), 8.8 (2H, s), 8.7(1H, t),8.5 (1H, s), 8.4 (1H, s), 7.9 (1H, s), 7.4 (4H, m), 7.3 (2H, m), 7.1(1H, m),4.9 (1H, m), 3.5 (1H, dd), 3.0 (2H, t),2.9(1H, dd),1.6-1.0(13H, m).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 50.75; H, 6.85; N, 18.42. C48H69NI5Ol3 .4.0H20 requires C, 50.74; H, 6.83; N, 18.49% ExamPle 14 5-(lS-(3,5-ditetrazolylphenylaminocarbonyl)-2- (2-fluorophenyl) ethylaminocarbonyl) -6- (cycloheptanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 13 except that BOC-L-2-fluorophenylalanine was used in step a instead of BOC-L-phenylalanine.The free ditetrazole was obtained on treating the bis ammonium salt with hydrochloric acid. 1H NMR (d6-DMSO) 6 10.4 (1H, s), 8.9 (1H, d), 8.8 (2H, s), 8.7(1H, t),8.5 (1H, s), 8.4 (1H, s), 7.9 (1H, s), 7.4 (1H, m), 7.3 (1H, m), 7.2(2H, m),7.1(1H, m),4.9 (1H, m), 3.6 (1H, dd), 3.1 (2H, m),2.9(1H, dd),1.6-1.0(13H, m).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found: C, 50.10; H, 6.74; N, 18.27. C48H68FNl5OI3 .4.0H2O requires C, 49.91 H, 6.72; N, 18.191 1 Example 15 5(15- (3-trifluoroacetylaminosulphonylphenyl- aminocarbonyl)-2-phenylethylaminocarbonyl)-6-(1 adamantanemethylaminocarbonyl) benz imidazole a.lS-(3-trifluoroacetylaminosulphonylphenylaminocarbonyl)2-phenylethylamine This was prepared in several steps starting with nitrobenzene-3-sulphonyl chloride. This was converted into the sulphonamide using ammonia in benzene. Trifluoroacetic anhydride was used to introduce the trifluoroacetyl group onto the sulphonamide.Catalytic hydrogenation reduced the nitro group to an amino function and this material was coupled to BOC-L-phenylalananine using the PyBROP method.
Removal of the BOC group was achieved with trifluoroacetic acid.
b. 5-(l-adamantanemethylaminocarbonyl) benzimidazole-6- carboxylic acid A solution of l-adamantanemethylamine (3.8g,22mmol) in THF (50ml) was added to a stirred solution of benzimidazole-5,6dicarboxylic anhydride (3.8g,20mmol) and triethylamine (6.lm1,44mmol) in THF (250ml) and the mixture was stirred at room temperature for lh. The solvent was partially evaporated to leave approximately 2/3 the original volume which was poured onto 2M hydrochloric acid (400ml). After standing at 5 C overnight the resultant white precipitate was filtered and dried to afford the title compound (7.55g).
c. 5-(lS-(3-trifluoroacetylaminosulphonylphenylamino- carbonyl) -2-phenylethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole The acid described in step b of this example and the amine from step a were coupled using the procedure described in example 1 step c. The crude precipitate was purified by boiling in a 1:1 mixture of dichloromethane and acetone followed by hot filtration. 1H NMR (d6-DMSO) s 10.1 (1H, s), 9.0-7.1 (15H, m), 4.8 (1H, m), 3.6-2.7 (4H, m), 1.9 (3H,s ), 1.6 (6H, m), 1.5 (6H, s). Found: C, 55.01; H,5.27; N, 10.33 C37H37F3N6O6S.3.0H20 requires C, 55.13; H, 5.39; N, 10.43t .
Example 16. 5-(1S-(3-benzoylaminosulphonylphenylamino- carbonyl) -2-phenylethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)benzimidazole This was prepared essentially as in example 15 except that benzoyl chloride was used in step a instead of trifluoroacetic anhydride.lH NMR (d6-DMSO) 8 13.5 (2H, br s), 10.2 (1H, s), 8.8 (1H, d), 8.6 (1H, t), 8.7-7.0 (17H, m), 4.8 (1H, m), 3.5-3.0 (4H, m), 1.9-1.4 (15H, m).
The compound was further characterised and tested as the Nmethyl-D-glucamine salt. Found: C, 57.49; H, 6.61; N, 9.72.
C4H59N7Q1S.3.7H2O requires C, 57.62; H, 6.56; N, 9.60%, Example 17 5(1S-(3,5-ditetrazolylphenylaminocarbonyl)-2- phenylethylaminocarbonyl) -6- (l-adamantanemethylamino- carbonyl)indole a. 3-Methyl-4-nitrophthalic acid The compound was prepared as in Organic Synthesis Collected Volume 1, 408 from 4-methylphthalic anhydride and fuming nitric acid.
b. Dimethyl 3-methyl-4-nitrophthalate The compound prepared in step a (4.4 g, 20 mmol) was suspended in methanol (100 ml) and concentrated sulphuric acid (2 ml) and the resulting suspension was heated under reflux for 48h. After cooling dichloromethane (100 ml) was added and the organic layer was washed with saturated sodium hydrogencarbonate solution. The aqueous layer was reextracted with dichloromethane (100 ml) and the combined organic layers were washed with washed with brine and dried.
The ssolution was filtered and evaporated to yield a white solid which was purified by recrystallisation from hot methanol. The title compound was isolated as white needles (3.14 g, 62%).
c. Dimethyl 3- (2-N, N-dimethylaminoethylene) -4-nitrophthalate The dimethyl ester prepared in step c above (3.14 g, 12.4 mmol) was dissolved in DMF (10 ml) and dimethylformamide dimethyl acetal (4.43 g, 37.2 mmol) was added. The reaction mixture was heated at 150 for 6h and then allowed to cool.
The solution was diluted with ethyl acetate (500 ml) and the solution was washed with brine (6 x 100 ml), dried filtered and evaporated to leave the title compound as a deep red solid (3.70 g, 97%).
d. 5,6-Dimethoxycarbonylindole The product of step c (1.50 g) was dissolved in toluene (200 ml) and 10% palladium on charcoal(150 mg) was introduced.
The reaction was stirred under an atmosphere of hydrogen at room temperature for lh. The catalyst was removed by filtration and the solvent by evaporation to leave the title compound (1.14 g).
e. Indole-5,6-dicarboxylic acid To a stirred solution of the dimethyl ester produced in step d (1.14 g, 4.9 mmol) in a 5:1 mixture of ethanol:water (12 ml) was added solid sodium hydroxide (0.49 g, 12.4 mmol).
The solution was stirred at a gentle reflux for 3h. The solution was acidifed on cooling to pH2 with hydrochloric acid and then evaporated. The residue was azeotroped with ethanol and then toluene and dried under vacuum. The residue was then extracted with hot acetone (5 x 20 ml) and the combined extracts were evaporated to leave the title compound (870 mg).
f. Indole-5,6-dicarboxylic acid anhydride The product of step e (870 mg) was heated strongly with a heat gun for 10 minutes under vacuum. This left the title compound (800 mg) g. 5-(lS-(3,5-ditetrazolylphenylaminocarbonyl)-2 phenylethylaminocarbonyl) -6- (l-adamantanemethylamino- carbonyl)indole This was prepared essentially as in example 10 except that indole-5,6-dicarboxylic acid anhydride was used in step b instead of benzlmidazole-5,6-dicarboxylic acid anhydride A mixture of regioisomers was obtained which was separated by column chromatography (silica 75% dichloromethane 25% ethyl acetate) immediately prior to final deprotection The less polar regioisomer was converted to the compound of this example. 'H NMR (d6-DMSO) 6 11.5 (1H, s), 10.4 (1H, s), 8.8 (3H, m), 8.5 (2H, m), 7.7 (1H, s), 7.5 (1H, t), 7.4-7.0 (6H, m), 6.5 (1H, s), 4.8 (1H, m), 3.5-2.9 (4H, m), 1.8 (3H, s), 1.5 (6H, q), 1.3 (6H, s).
The compound was further characterised and tested as the Nmethyl-D-glucamine salt. Found: C, 53.94; H, 6.91; N, 16.73. C52HnNl4OI3.3H2O requires C, 54.06; H, 6.80; N, 16.97% ExamPle 18 6-(1S-(3,5-ditetrazolylphenylaminocarbonyl)-2- phenylethylaminocarbonyl) -5- (1-adamantanemethylamino- carbonyl)indole This was prepared essentially as in example 17 except that the more polar regioisomer isolated when regioisomers were separated was converted to the title compound. 'H NMR (d6 DMSO) 8 11.5 (1H, s), 10.4 (1H, s), 8.8 (3H, m), 8.5 (2H, m), 7.9 (1H, s), 7.5 (1H, t), 7.4-7.0 (6H, m), 6.6 (1H, s), 4.8 (1H, m), 3.6-2.9 (4H, m), 1.8 (3H, s), 1.5 (6H, q), 1.3 (6H, s).
The compound was further characterised and tested as the Nmethyl-D-glucamine salt. Found: C, 54.21; H, 6.62; N, 16.81. C52H72N,40,3.3H20 requires C, 54.06; H, 6.80; N, 16.97% Example 19 5-(1R-(3,5-dicarboxyphenylaminocarbonyl)-2-(2- fluorophenyl) ethylaminocarbonyl) -6- (1-adamantanemethyl- aminocarbonyl)-benzimidazole The material is prepared essentially as in example 1 except that BOC-D-2-fluorophenylalanine is used in step g instead of BOC-L-2-fluorophenylalanine. 'H NMR (d6-DMSO) 6 13.0 (3H, br s), 10.2 (1H, br s), 8.9 (1H, d), 8.74 (2H, s), 8.7 (1H, t), 8.4 (1H, s), 8.2 (1H, s), 7.8 (1H, s), 7.5-7.1 (5H, m), 4.8 (1H, m), 3.5 (1H, m), 3.3-3.1 (3H, m), 1.6-1.1 (13H, m).
Example 20 (comparative) 5-(lS-(3, 5-dicarboxyphenyl- aminocarbonyl) -2-phenylethylaminocarbonyl) -6- (1- adamantylmethylaminocarbonyl)indole.
A solution of indole-5,6-dicarboxylic anhydride (1.87g,10mmol) and lS-(3,5-dibenzyloxycarbonylphenylamino- carbonyl)-2-phenylethylamine (4.96g,9.8mmol) in dry acetonitrile (100ml) was heated under reflux for 30min..
The mixture was cooled and stood at room temperature overnight. The resultant white precipitate was filtered and dried to give 5- (15- (3 , 5-dibenzyloxycarbonylphenylamino- carbonyl)-2-phenylethylaminocarbonyl)-6-(1-adamantyl- methylaminocarbonyl)-indole (3.25g) This was hydrogenolysed, following the procedure used in example 1 step d, to give the title compound. 'H NMR (d6-DMSO) s 11.5 (1H, s), 10.2 (1H, s), 8.7 (1H, d), 8.6 (2H, s), 8.4 (1H, t), 8.2 (1H, s), 7.7 (1H, s), 7.5 (1H, s), 7.2 (6H, m), 6.5 (1H, s), 4.8 (1H, m), 3.5 (1H, m), 3.0 (3H, m), 1.8 (3H, s), 1.5 (6H, m), 1.4 (6H, s).
The compound was further characterised and tested as the di N-methyl-D-glucamine salt. Found : C, 58.05; H, 6.99; N, 7.88. C52H72N6OX7.H2O requires C, 58.31; H, 6.96; N, 7.85%.
The compounds of the examples were tested using the following in vivo assays: 1. Ghosh and Schild anaesthetised rat preparation (intravenous drug administration) Rats were fasted overnight with free access to water. They were anaesthetised with 1.8ml/kg urethane 20tw.v. i.p.. A midline incision was made in the abdomen and the pyloric sphincter and the cardiac sphincters were cannulated using small plastic tubing. The jugular veins were cannnulated and tracheotomy was also carried out. The rats were placed on a temperature regulated mat (37-39 C) to maintain body temperature and the stomachs were perfused at lml/min with a glucose-containing electrolyte solution. The pH of the perfusate exiting the stomach was measured continuously.
The rats were allowed to stabilise for approximately 1520min. leading to a satisfactory baseline pH. Pentagastrin infusion (sub-maximal acid secretory dose 0.1pg/kg/min) was administered via a jugular vein. Pentagastrin induced acid secretion took approximately 5min. to begin and usually stabilised within 30min. A bolus dose of the test compound was administered via the contralateral jugular vein and the pH response monitored for 60min. Responses were measured as the peak percentage with respect to the change in pH evoked by pentagastrin infusion over the baseline. The results obtained are set out in Table 1.
Table 1
Example Example i.v. dose % i.v.
No. pmol/kg inhibition 1 0.1 55 2 0.025 38 3 0.025 37 4 0.1 62 5 0.025 60 6 0.025 66 7 0.025 47 8 0.025 38 9 0.1 39 10 0.025 81 11 0.025 58 12 0.025 63 13 0.025 28 14 0.025 35 15 0.025 44 16 0.025 47 17 0.025 62 2. Conscious, chronic gastric fistula beagle dogs (intragastric drug administration) Dogs with chronic in-dwelling gastric fistula were fasted overnight with free access to water.They were placed on a table and lightly restrained. The gastric fistula was opened, cleared of food debris and flushed with up to 30ml of tepid water. Thereafter the gastric contents were collected under gravity every 15min. and the total titratable acidity ws determined against 0.01M NaOH. After a 30min settling period 50ml of water or a solution of the test compound was instilled into the stomach via the gastric fistula and the fistula sealed for 45min. After 45min. the fistula was opened, any stomach contents collected and titrated as before. A single sub-maximal, subcutaneous injection of pentagastrin (4-8pg/kg) was administered into the scruff and the subsequent gastric secretions were collected over the following 75min at 15min intervals. The acid secreted over the test 75min period was aggregated and compared with the typical response of each individual dog to pentagastrin challenge in the absence of drug as assessed from the mean of the last 6 control studies. Results are set out in Table 2, expressed as the percentage inhibition. Table 2
Example i.g. dose % i.g.
No. ymol/kg inhibition 1 5 47 2 10 27 3 10 35 4 5 50 5 10 58 6 10 45 7 2.5 22 8 2.5 35 9 10 49 10 10 48 11 5 41 12 10 44 13 2.5 43 14 25 39 15 10 21 16 10 45 17 10 59 18 5 24 20* 40 i.a.
* (comparative) i.a.= inactive as tested 3. Conscious, chronic gastric fistula beagle dogs (intravenous drug administration) Animals were prepared as above and an intravenous cannula with a two-way tap was placed in the foreleg vein for continuoous infusion of initially saline and subsequently pentagastrin to evoke a background, sub-maximal acid secretory response. 1 hour after commencing the pentagastrin infusion a bolus dose of the test compound was administered and the response monitored for at least 1 further hour. Responses were measured as the peak percentage reduction in acid secretion with respect to the pre-dose 15min sample. Results are set out in Table 3.
Table 3
Example i.v. dose % i.v.
No. Amol/kg inhibition 1 0.025 48 4 0.05 76 5 0.025 87 10 0.0067 56 11 0.0067 83

Claims (10)

  1. CLAIMS 1. A compound of the formula
    wherein L is =N- or =CH-, one of X and Y is -NH-CH2-R2 (wherein R2 is cycloheptyl or 1-adamantyl) and the other is
    in which Rl is H or methyl, Tl and T2 are independently H or Z(CH2)m-, wherein m is from 0 to 3 and Z is a carboxy group, a tetrazolyl group, CF3CONHSO2-, PhCONHSO2- or a group selected from
    (provided that Tl and T2 are not both H and that T and T2 are not both carboxy when L is =CH-); and n is from 0 to 5 or a pharmaceutically acceptable salt or physiological precursor thereof.
  2. 2. A compound according to claim 1, wherein L is =N-.
  3. 3. A compound according to any preceding claim wherein
  4. 4. A compound according to claim 2 wherein n=O and Tl and T2 are other than carboxy.
  5. 5. A compound according to any preceding claim wherein m=O.
  6. 6. A method of preparing a compound according to any preceding claim, said method comprising the steps of a) reacting a compound of the formula
    with a compound of the formula H2N-CH2-R2 wherein L and R2 are as defined in claim 1, b) reacting the product with a compound of the formula
    wherein Rl and n are as defined in claim 1, and T3 and T4 are independently H or Z'(CH2)n,- (wherein m is from O to 3 and Z' is a protected carboxy group, a protected tetrazolyl group, CF3CONHSO2-, PhCONHSO2- or a suitable precursor group such as HO- or H2N-), and c) deprotecting and/or functionalising T3 and/or T' if required.
  7. 7. A method of preparing a compound according to any of claims 1 to 5, said method comprising the steps of a) reacting a compound of the formula
    with a compound of the formula
    wherein Rl, L and n are as defined in claim 1, and T3 and r4 are as defined in claim 3, b) reacting the product with a compound of the formula H2N-CH2-R2 wherein R2 is as defined in claim 1, and c) deprotecting and/or functionalising T3 and/or T4 if required.
  8. 8. A pharmaceutical composition comprising a compound according to any of claims 1 to 5 in admixture with a pharmaceutically acceptable excipient or carrier.
  9. 9. A composition according to claim 8, being adapted for oral administration.
  10. 10. A method of preparing a pharmaceutical composition according to claim 8 or claim 9 comprising admixing a compound according to any of claims 1 to 5 with a pharmaceutically acceptable excipient or carrier.
GB9502503A 1994-05-27 1995-02-09 Indole and benzimidazole gastrin and CCK antagonists Withdrawn GB2290539A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP95919561A EP0763026B1 (en) 1994-05-27 1995-05-25 Gastrin and cck antagonists
JP8500483A JPH10504525A (en) 1994-05-27 1995-05-25 Gastrin and CCK antagonist
AU25342/95A AU2534295A (en) 1994-05-27 1995-05-25 Gastrin and cck antagonists
US08/737,725 US5912260A (en) 1994-05-27 1995-05-25 Gastrin and CCK antagonists
AT95919561T ATE235470T1 (en) 1994-05-27 1995-05-25 GASTRIN AND CCK ANTAGONISTS
PCT/GB1995/001194 WO1995032949A1 (en) 1994-05-27 1995-05-25 Gastrin and cck antagonists
DE69530081T DE69530081T2 (en) 1994-05-27 1995-05-25 GASTRIN AND CCK ANTAGONISTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410688A GB9410688D0 (en) 1993-08-10 1994-05-27 Gastrin and CCK receptor ligands
PCT/GB1994/001741 WO1995004720A2 (en) 1993-08-10 1994-08-09 Gastrin and cck receptor ligands

Publications (2)

Publication Number Publication Date
GB9502503D0 GB9502503D0 (en) 1995-03-29
GB2290539A true GB2290539A (en) 1996-01-03

Family

ID=26304236

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9502503A Withdrawn GB2290539A (en) 1994-05-27 1995-02-09 Indole and benzimidazole gastrin and CCK antagonists

Country Status (1)

Country Link
GB (1) GB2290539A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085724A1 (en) * 2000-05-08 2001-11-15 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands (iii)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085724A1 (en) * 2000-05-08 2001-11-15 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands (iii)
GB2377442A (en) * 2000-05-08 2003-01-15 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
GB2377442B (en) * 2000-05-08 2004-08-04 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
US7034048B2 (en) 2000-05-08 2006-04-25 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands (III)

Also Published As

Publication number Publication date
GB9502503D0 (en) 1995-03-29

Similar Documents

Publication Publication Date Title
EP0763026B1 (en) Gastrin and cck antagonists
US5939437A (en) CCK and gastrin receptor ligands
US5919829A (en) Gastrin and cck receptor ligands
US5795907A (en) Gastin and CCK receptor ligands
US6956053B2 (en) Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands
JP2593022B2 (en) Aminoguanidines
DE69411317T2 (en) Indoloylguanidine derivatives as inhibitors of sodium proton exchange
WO1994014801A1 (en) Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
US20030195240A1 (en) Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands
US7714130B2 (en) Processes for preparing gonadotropin releasing hormone receptor antagonists
US7034048B2 (en) Gastrin and cholecystokinin receptor ligands (III)
US5514683A (en) Bicyclo 2,2,2!octane derivatives
EP0719251B1 (en) Bicyclo (2.2.2) octane derivatives cholecystokinin and/or gastrin antagonists
AU630397B2 (en) 4,5,6,7-tetrahydrobenzimidazole derivatives
GB2290539A (en) Indole and benzimidazole gastrin and CCK antagonists
KR101343399B1 (en) Proline analogs as ligands for cannabinoid receptors for the treatment of pain
WO2003057214A1 (en) Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
FI63752C (en) PROCEDURE FOR THE FRAMSTATION OF AV 1-BENZOYL-2- (2 &#39;, 6&#39;-DICHLOROPHENYLAMINO) -2-IMIDAZOLINE AND DESS SALTER
RU2033414C1 (en) Derivatives of 4,5,6,7-tetrahydrobenzimidazole
KR100299419B1 (en) Gastrin and CCK Receptor
US20070082892A1 (en) Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands
NZ202687A (en) Oxygen derivatives of 3,7a-diazacyclohepta(j,k)fluorenes and pharmaceutical compositions
GB2268739A (en) Bicyclo [2.2.2.] octene derivatives

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)